Combined aerobic/resistance/inspiratory muscle training as the ‘optimum’ exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial

Author:

Laoutaris Ioannis D1,Piotrowicz Ewa2,Kallistratos Manolis S3,Dritsas Athanasios1,Dimaki Niki3,Miliopoulos Dimitris1,Andriopoulou Maria3,Manolis Athanasios J3,Volterrani Maurizio4,Piepoli Massimo F5,Coats Andrew J S4,Adamopoulos Stamatis1,

Affiliation:

1. Heart Failure and Transplant Unit, Onassis Cardiac Surgery Center, 356 Sygrou Boulevard, 176 74 Athens, Greece

2. National Institute of Cardiology, Telecardiology Center, Alpejska 42, 04-628, Warsaw, Poland

3. Cardiology Department, Asklepieion General Hospital, Alpejska 42, 04-628, Athens, Greece

4. Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, via della Pisana 235, 00163, Rome, Italy

5. Heart Failure Unit, Cardiac Department, G. da Saliceto Hospital, via taverna Giuseppe 49, 291121, AUSL, Piacenza, Italy

Abstract

Abstract Aims An ‘optimum’ universally agreed exercise programme for heart failure (HF) patients has not been found. ARISTOS-HF randomized clinical trial evaluates whether combined aerobic training (AT)/resistance training (RT)/inspiratory muscle training (IMT) (ARIS) is superior to AT/RT, AT/IMT or AT in improving aerobic capacity, left ventricular dimensions, and secondary functional outcomes. Methods and results Eighty-eight patients of New York Heart Association II–III, left ventricular ejection fraction  ≤ 35% were randomized to an ARIS, AT/RT, AT/IMT, or AT group, exercising 3 times/week, 180 min/week for 12 weeks. Pre- and post-training, peakVO2 was evaluated with cardiopulmonary exercise testing, left ventricular dimensions using echocardiography, walking distance with the 6-min walk test (6MWT), quality of life by the Minnesota Living with HF Questionnaire (MLwHFQ), while a programme preference survey (PPS) was used. Seventy-four patients of [mean 95% (confidence interval, CI)] age 66.1 (64.3–67.9) years and peakVO2 17.3 (16.4–18.2) mL/kg/min were finally analysed. Between-group analysis showed a trend for increased peakVO2 (mL/kg/min) [mean contrasts (95% CI)] in the ARIS group [ARIS vs. AT/RT 1.71 (0.163–3.25)(.), vs. AT/IMT 1.50 (0.0152–2.99)(.), vs. AT 1.38 (−0.142 to 2.9)(.)], additional benefits in circulatory power (mL/kg/min⋅mmHg) [ARIS vs. AT/RT 376 (60.7–690)*, vs. AT/IMT 423 (121–725)*, vs. AT 345 (35.4–656)*], left ventricular end-systolic diameter (mm) [ARIS vs. AT/RT −2.11 (−3.65 to (−0.561))*, vs. AT −2.47 (−4.01 to (−0.929))**], 6MWT (m) [ARIS vs. AT/IMT 45.6 (18.3–72.9)**, vs. AT 55.2 (27.6–82.7)****], MLwHFQ [ARIS vs. AT/RT −7.79 (−11 to (−4.62))****, vs. AT −8.96 (−12.1 to (−5.84))****], and in PPS score [mean (95% CI)] [ARIS, 4.8 (4.7–5) vs. AT, 4.4 (4.2–4.7)*] [(.) P ≤ 0.1; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001]. Conclusion ARISTOS-HF trial recommends exercise training for 180 min/week and supports the prescription of the ARIS training regime for HF patients (Clinical Trial Registration: http://www.clinicaltrials.gov. ARISTOS-HF Clinical Trial number, NCT03013270).

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3